On June 16, 2017, 107.3 million shares were listed on SIX.
In June 2017, 11.8 million shares issued through the conversion of the first tranche of the convertible loan provided by Cilag Holding AG, an indirect subsidiary of Johnson & Johnson, were listed. In November 2021, a second tranche of the convertible loan was converted and Cilag acquired 9.6 million shares of the Group. The remaining amount of the convertible loan may be converted into 29.1 million shares.
In July 2018, the Group privately placed 11.9 million new registered shares. Concurrently to the private placement of new shares, the Group issued CHF 200 million of senior unsecured convertible bonds. The Bonds mature on July 17, 2024, and are convertible into 5.9 million registered shares of the Group.
In May 2020, the Group privately placed 11 million new registered shares.
In October 2020, the Group issued 23.8 million new registered shares.
In August 2021, the Group placed CHF 600 million senior unsecured convertible bonds due 2028 convertible into 19.0 million shares of the Group.
In January 2023, the Group created 10 million treasury shares.
Idorsia Ltd is part of the following indices: SPI, SPIEX, SPI ESG, SXSLI, SXI Life Sciences, SXI Bio+Medtech, and SSIRT.
Idorsia is traded under the following symbols: Reuters IDIA.S / Bloomberg IDIA:SW.